Answers are grounded in this paper and cite their sources.
Implementation analysis reports clinical promise and safety risks of amyloid-targeting therapy in Alzheimer's disease, highlighting the need for interprofessional teams.
Lecanemab and other new amyloid-targeting immunotherapies for Alzheimer's disease show great promise but, may also pose significant risk for patients.
No takes yet. Share an insight, caveat, or question.
Turk et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: